Peripheral blood progenitor cell product contains Th1-biased noninvariant CD1d-reactive natural killer T cells: Implications for posttransplant survival

Experimental Hematology

Volumn 36, Issue 4, 2008, Pages 464-472

  Shaulov, Angela ^a   Yue, Simon ^a   Wang, RuoJie ^a   Joyce, Robin M ^a   Balk, Steven P ^a   Kim, Haesook T ^b   Avigan, David E ^a   Uhl, Lynne ^a   Sackstein, Robert ^c   Exley, Mark A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR ALPHA CHAIN;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER IMMUNOLOGY; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOREGULATION; MALE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL;

ADULT; ANTIGENS, CD1; CELL SEPARATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TH1 CELLS; TREATMENT OUTCOME;

EID: 40649103844     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.12.010     Document Type: Article

References (32)

1. Talmadge J.E. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. Int Immunopharmacol 3 (2003) 1121-1143
2. Slavin S., Morecki S., Weiss L., Shapira M.Y., Resnick I., and Or R. Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy: from bench to patient bedside. Semin Oncol 31 (2004) 4-21
3. Pillai A., George T., Dutt S., Teo P., and Strober S. Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation. J Immunol 178 (2007) 6242-6251
4. Sykes M., Hoyles K., Romick M., and Sachs D. In vitro and in vivo analysis of bone marrow-derived CD3+, CD4-, CD8-, NK1.1+ cell lines. Cell Immunol 129 (1990) 487-493
5. Zeng D., Lewis D., Dejbakhsh-Jones S., et al. Bone marrow NK1.1- and NK1.1+ T cells reciprocally regulate acute graft versus host disease. J Exp Med 189 (1999) 1073-1081
6. Johnson B.D., Becker E.E., LaBelle J.L., and Truitt R.L. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. J Immunol 163 (1999) 6479-6487
7. Strober S. Natural killer 1.1(+) T cells and "natural suppressor" T cells in the bone marrow. J Allergy Clin Immunol 106 (2000) S113-S114
8. Schmidt-Wolf I., Dejbakhsh-Jones S., Ginzton N., Greenberg P., and Strober S. T-cell subsets and suppressor cells in human bone marrow. Blood 80 (1992) 3242-3250
9. Kusnierz-Glaz C., Still B., Amano M., et al. Granulocyte colony-stimulating factor-induced co-mobilization of CD4- CD8- T cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors. Blood 89 (1997) 2586-2595
10. Exley M., Tahir S., Cheng O., et al. Cutting edge: a major fraction of human bone marrow lymphocytes are Th2-Like CD1d-reactive NKT that can suppress mixed lymphocyte responses. J Immunol 167 (2001) 5531-5534
11. Zeng D., Gazit G., Dejbakhsh-Jones S., et al. Heterogeneity of NK T cells in the bone marrow: divergence from thymus. J Immunol 163 (1999) 5338-5345
12. Lowsky R., Takahashi T., Liu Y.P., et al. Protective conditioning for acute GVHD. N Engl J Med 353 (2005) 1321-1331
13. -T cells. J Exp Med 186 (1997) 109-120
14. Godfrey D.I., and Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114 (2004) 1379-1388
15. Exley M., Furman M., Porcelli S., and Balk S. CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant Vα24JαQ TCRα chains. J Exp Med 188 (1999) 867-876
16. Exley M.A., He Q., Cheng O., et al. Cutting edge: compartmentalization of Th1-like non-invariant CD1d-reactive NKT in hepatitis C virus-infected liver. J Immunol 168 (2002) 1519-1523
17. Durante-Mangoni E., Wang R., Shaulov A., et al. Hepatic CD1d expression in hepatitis C virus infection and recognition by resident pro-inflammatory CD1d-reactive NKT. J Immunol 173 (2004) 2159-2166
18. Fuss I., Heller F., Boirivant M., et al. Non-classical CD1d-restricted NKT cells that produce IL-13 characterize an atypical Th2 response in Ulcerative Colitis. J Clin Invest 113 (2004) 1490-1497
19. Exley M., and Koziel M. To be or not to be: NKT cells in the liver. Hepatology 40 (2004) 1033-1040
20. Levy O., Orange J., Hibberd P., et al. Disseminated varicella infection due to vaccine (Oka) strain Varicella zoster virus in a patient with a novel deficiency in natural killer T cells. J Infect Dis 188 (2003) 948-953
21. Tahir M., Cheng O., Shaulov A., Bubley G., Balk S., and Exley M. Loss of IFN-γ production by invariant NK T cells of advanced cancer patients. J Immunol 167 (2001) 4046-4050
22. Palathumpat V., Dejbakhsh-Jones S., Holm B., and Strober S. Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease. J Immunol 149 (1992) 808-817
23. Hashimoto D., Asakura S., Miyake S., et al. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol 174 (2005) 551-556
24. Haraguchi K., Takahashi T., Matsumoto A., et al. Host-residual invariant NK T cells attenuate graft-versus-host immunity. J Immunol 175 (2005) 1320-1328
25. Morris E.S., MacDonald K.P., Rowe V., et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. J Clin Inv 115 (2005) 3093-3103
26. Patterson S., Kotsianidis I., Almeida A., et al. Human invariant NKT cells are required for effective in vitro allo-responses. J Immunol 175 (2005) 5087-5094
27. + NKT cells. J Immunol 173 (2004) 4960-4966
28. Hartung T., Docke W.D., Gantner F., et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 85 (1995) 2482-2489
29. Sloand E.M., Kim S., Maciejewski J.P., et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 95 (2000) 2269-2274
30. Terabe M., Swann J., Ambrosino E., et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202 (2005) 1627-1633
31. Kotsianidis I., Silk J.D., Spanoudakis E., et al. Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood 107 (2006) 3138-3144
32. Broxmeyer H.E., Dent A., Cooper S., et al. A role for natural killer T cells and CD1d molecules in counteracting suppression of hematopoiesis in mice induced by infection with murine cytomegalovirus. Exp Hematol 35 (2007) 87-93